Fig 1A



% Capillary network length
110
100
90
80
70
60
50
40
*
*
+70%
Control
Abeta 1-42
2.5µM
VEGF
10nM

Fig 1B




% Capillary network length
110
100
90
80
70
60
50
40
*
*
+44%
Control
Ab1-42
2.5µM
Ab1-42 2.5µM
+ Torasemide 400nM

Fig 1C


% Capillary network length
110
100
90
80
70
60
50
40
*
*
+36%
Control
Ab1-42
2.5µM
Ab1-42 2.5µM
+ Bromocriptine 3.2nM



A
% Cell toxicity
160
140
120
100
80
60
40
-70%
Control
Ab1-42 10µM
Ab1-42 10µM + Estradiol 150nM
B
% Cell toxicity
-29%
Control
Ab1-42 10µM
Ab1-42 10µM + Bromocriptine 40nM
C
% Cell toxicity
-94%
Control
Ab1-42 10µM
Ab1-42 10µM + Trimetazidine 40nM
D
% Cell toxicity
-94%
Control
Ab1-42 10µM
Ab1-42 10µM + Ifenprodil 600nM

FIGURE 2



E
F
% Cell toxicity
160
140
120
100
80
60
40
*
◊
-73%
-63%
Control
Ab1-42 10µM
Ab1-42 10µM + Mexiletine 3.2nM
Ab1-42 10µM + Moxifloxacin 20nM

FIGURE 2



A
% Capillary network length
110
100
90
80
70
60
50
40
Control
Abeta 1-42 2.5µM
Ab1-42 2.5µM + Baclofen 2µM + Torasemide 80nM
+58%
*
◇
B
% Capillary network length
Control
Ab1-42 2.5µM
Ab1-42 2.5µM + Baclofen 2µM
ns
*
C
% Capillary network length
Control
Ab1-42 2.5µM
Ab1-42 2.5µM + Torasemide 80nM
ns
*

FIGURE 3



A
% Capillary network length
110
100
90
80
70
60
50
40
Control
Abeta 1-42 2.5µM
Ab1-42 2.5µM + Sulfisoxazole 1.36nM + Torasemide 80nM
+25%
*
◇
B
% Capillary network length
Control
Ab1-42 2.5µM
Ab1-42 2.5µM + Sulfisoxazole 1.36nM
ns
*
C
% Capillary network length
Control
Ab1-42 2.5µM
Ab1-42 2.5µM + Torasemide 80nM
ns
*

FIGURE 4



A
% Capillary network length
110
100
90
80
70
60
50
40
Control
Abeta 1-42 2.5µM
Ab1-42 2.5µM + Torasemide 80nM+ Eplerenone 400nM
+59%
*
◈
B
% Capillary network length
Control
Ab1-42 2.5µM
Ab1-42 2.5µM + Torasemide 80nM
ns
*
C
% Capillary network length
Control
Ab1-42 2.5µM
Ab1-42 2.5µM + Eplerenone 400nM
ns
*

FIGURE 5



A
% Capillary network length
110
100
90
80
70
60
50
40
Control
Abeta 1-42 2.5µM
Ab1-42 2.5µM + Sulfisoxazole 1.36nM + Bromocriptine 0.64nM
+26%
*
◇
B
% Capillary network length
Control
Ab1-42 2.5µM
Ab1-42 2.5µM + Bromocriptine 0.64nM
ns
*
C
% Capillary network length
Control
Ab1-42 2.5µM
Ab1-42 2.5µM + Sulfisoxazole 1.36nM
ns
*

FIGURE 6



A
B
C
% Cell toxicity
180
160
140
120
100
80
60
40
Control
Abeta 1-42 10µM
Ab1-42 10µM + Acamprosate 320pM + Ifenprodil 24nM
Ab1-42 10µM + Acamprosate 320pM
Ab1-42 10µM + Ifenprodil 24nM
-33%
*
ns

FIGURE 7



A
B
C
% Cell toxicity
Control
Abeta 1-42 10µM
Ab1-42 10µM + Baclofen 80nM + Mexiletine 25.6pM
Ab1-42 10µM + Baclofen 80nM
Ab1-42 10µM + Mexiletine 25.6pM
-23%
ns
*

FIGURE 8



A
B
C
% Cell toxicity
Control
Abeta 1-42 10µM
Ab1-42 10µM + Baclofen 80nM + Trimetazidine 320pM
Ab1-42 10µM + Baclofen 80nM
Ab1-42 10µM + Trimetazidine 320pM
-51%
ns
*

FIGURE 9



A
B
C
% Cell toxicity
Control
Abeta 1-42 10µM
Ab1-42 10µM + Cinacalcet 64pM + Mexiletine 25.6pM
Ab1-42 10µM + Cinacalcet 64pM
Ab1-42 10µM + Mexiletine 25.6pM
-46%
ns
*

FIGURE 10



A
% Cell toxicity
180
160
140
120
100
80
60
40
Control
Abeta 1-42 10µM
Ab1-42 10µM + Cinnarizine 160pM + Trimetazidine 320pM
-39%
*
◈
B
ns
Control
Abeta 1-42 10µM
Ab1-42 10µM + Cinnarizine 160pM
C
Control
Abeta 1-42 10µM
Ab1-42 10µM + Trimetazidine 320pM

FIGURE 11



A
B
C
% Cell toxicity
180
160
140
120
100
80
60
40
Control
Abeta 1-42 10µM
Ab1-42 10µM + Trimetazidine 320pM
Ab1-42 10µM + Zonisamide 320pM
Ab1-42 10µM + Trimetazidine 320pM + Zonisamide 320pM
-37%
*
ns
◈

FIGURE 12



B
% Capillary network length
110
100
90
80
70
60
50
40
Control
Ab1-42 2.5µM
ns
*
Ab1-42 2.5µM + Terbinafine 1.5µM
C
% Capillary network length
Control
Ab1-42 2.5µM
ns
*
Ab1-42 2.5µM + Torasemide 80nM
A
% Capillary network length
Control
Abeta 1-42 2.5µM
*
+18%
*
Ab1-42 2.5µM + Terbinafine 1.5µM + Torasemide 80nM

FIGURE 13



A
B
C
% Capillary network length
110
100
90
80
70
60
50
40
Control
Ab1-42 2.5µM
Ab1-42 2.5µM + Cinacalcet 64pM + Mexiletine 25.6pM
Ab1-42 2.5µM + Cinacalcet 64pM
Ab1-42 2.5µM + Mexiletine 25.6pM
+29%
*
◇ *
ns

FIGURE 14



% LDH
140
130
120
110
100
90
80
70
60
Control
Abeta 1-42 10µM
Ab1-42 10µM + Baclofen 400nM + Torasemide 80nM
-83%
Abeta 1-42 10µM + Baclofen 400nM
Abeta 1-42 10µM + Torasemide 80nM
*
*
*

FIGURE 15



A
B
C
% LDH
160
140
120
100
80
60
40
Control
Abeta 1-42 10µM
Ab1-42 10µM + Torasemide 80 nM + Sulfisoxazole 1.36 nM
-52%
ns
Abeta 1-42 10µM + Torasemide 80 nM
Abeta 1-42 10µM + Sulfisoxazole 1.36 nM

FIGURE 16




A
B
C
% LDH
Control
Abeta 1-42 10µM
Ab1-42 10µM + Moxifloxacin 4nM + Trimetazidine 320pM
Abeta 1-42 10µM + Moxifloxacin 4nM
Abeta 1-42 10µM + Trimetazidine 320pM
-58%
-29%
ns
*
◇

FIGURE 17


B
ns
*
*
Abeta 1-42 10µM + Moxifloxacin 4nM
Abeta 1-42 10µM
Control
% LDH
150
140
130
120
110
100
90
80
70
60
C
ns
*
*
Abeta 1-42 10µM + Baclofen 80nM
Abeta 1-42 10µM
Control
% LDH
150
140
130
120
110
100
90
80
70
60



A
-50%
*
*
Ab1-42 10µM + Moxifloxacin 4nM+ Baclofen 80nM
Abeta 1-42 10µM
Control
% LDH
160
140
120
100
80
60
40

FIGURE 18



A
B
C
% LDH
Control
Abeta 1-42 10µM
Ab1-42 10µM + Moxifloxacin 4nM + Cinacalcet 64pM
Abeta 1-42 10µM + Moxifloxacin 4nM
Abeta 1-42 10µM + Cinacalcet 64pM
-53%
ns
*

FIGURE 19



A
B
C
% LDH
Control
Abeta 1-42 10µM
Ab1-42 10µM + Moxifloxacin 4nM + Zonisamide 320pM
Abeta 1-42 10µM + Moxifloxacin 4nM
Abeta 1-42 10µM + Zonisamide 320pM
-58%
-32%
ns
*

FIGURE 20



A
B
C
% LDH
Control
Abeta 1-42 10µM
Ab1-42 10µM + Moxifloxacin 4nM + Sulfisoxazole 55pM
-70%
Abeta 1-42 10µM + Moxifloxacin 4nM
Abeta 1-42 10µM + Sulfisoxazole 55pM
ns
*

FIGURE 21




FIGURE 22




FIGURE 23




FIGURE 24




FIGURE 25




FIGURE 26



% LDH Release
160
140
120
100
80
60
Control
Abeta 1-42 10µM
Abeta 10µM + Homotaurine 8nM
Abeta 10µM + Acamprosate 8nM
*

FIGURE 27